Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
mi
from
Toronto,
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
mi
from
Toronto,
Click here to add this to my saved trials
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Stony Brook, NY
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Barcelona,
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Swedish Health Services
mi
from
Seattle, WA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Swedish Health Services
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Scottsdale, Arizona
mi
from
Scottsdale, AZ
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Scottsdale, Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
St. Josephs Hospital
mi
from
Orange, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
St. Josephs Hospital
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital
mi
from
Santa Rosa, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Innovative Clinical Research
mi
from
Whittier, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Innovative Clinical Research
mi
from
Whittier, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospitals
mi
from
Fort Lauderdale, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospitals
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Miami/Sylvester Cancer Center
mi
from
Miami, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Miami/Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona /ID# 148582
mi
from
Phoenix, AZ
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona /ID# 148582
mi
from
Phoenix, AZ
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Scottsdale Healthcare /ID# 151349
mi
from
Scottsdale, AZ
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Scottsdale Healthcare /ID# 151349
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of California, Los Angeles /ID# 148586
mi
from
Los Angeles, CA
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of California, Los Angeles /ID# 148586
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Univ of Colorado Cancer Center /ID# 148581
mi
from
Aurora, CO
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Univ of Colorado Cancer Center /ID# 148581
mi
from
Aurora, CO
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 148579
mi
from
Chicago, IL
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 148579
mi
from
Chicago, IL
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Dana Farber Cancer Institute /ID# 143782
mi
from
Boston, MA
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dana Farber Cancer Institute /ID# 143782
mi
from
Boston, MA
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine /ID# 151348
mi
from
Saint Louis, MO
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine /ID# 151348
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center /ID# 150786
mi
from
New York, NY
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center /ID# 150786
mi
from
New York, NY
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr /ID# 148200
mi
from
Durham, NC
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr /ID# 148200
mi
from
Durham, NC
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute, PLLC /ID# 148583
mi
from
Huntersville, NC
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute, PLLC /ID# 148583
mi
from
Huntersville, NC
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania /ID# 148576
mi
from
Philadelphia, PA
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania /ID# 148576
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Greenville Hospital System /ID# 148652
mi
from
Greenville, SC
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Greenville Hospital System /ID# 148652
mi
from
Greenville, SC
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research /ID# 148580
mi
from
Dallas, TX
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research /ID# 148580
mi
from
Dallas, TX
Click here to add this to my saved trials
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Univ TX, MD Anderson /ID# 147681
mi
from
Houston, TX
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Univ TX, MD Anderson /ID# 147681
mi
from
Houston, TX
Click here to add this to my saved trials